A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Exclusion criteria

• Participant had permanently discontinued from sotorasib study treatment in the parent study before the parent study's completion. • Ongoing, unresolved toxicity requiring interruption of sotorasib treatment at the time of the termination of the parent study. • Local access to commercially available investigational product(s) at no cost to the participant as permitted by local/country regulation. • Anticipated toxicities of sotorasib study treatment outweigh the clinical benefit to the participant in the opinion of the investigator. • Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements, in the judgment of the individual and investigator. • Significant uncontrolled concomitant disease that could affect compliance with protocol procedures or interpretation of results or that pose a risk to participant safety, in the opinion of the investigator. • Female participants of childbearing potential unwilling to use protocol-specified method of contraception during treatment and for an additional: • 7 days after the last dose of sotorasib. • 2 months after the last dose of panitumumab. • Female participants who are breastfeeding or who plan to breastfeed while on study through: • 7 days after the last dose of sotorasib. • 2 months after the last dose of panitumumab. • Female participants planning to become pregnant while on study through: • 7 days after the last dose of sotorasib. • 2 months after the last dose of panitumumab. • Female participants of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a highly sensitive urine or serum pregnancy test. • Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 7 days after the last dose of sotorasib. • Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 7 days after the last dose of sotorasib. • Male participants unwilling to abstain from donating sperm during treatment and for an additional 7 days after the last dose of sotorasib.